Business Model Canvas (BMC)- A new venture concept
Indian pharmaceutical
1. SHANKAR R 14114
GEORGE JACOB 14095
DIVYA LIZ GEORGE 14093
DHARA B SHAH 14067
MARY MONISHA 14060
G5
INDIAN PHARMACEUTICAL INDUSTRY
Committed to a healthier
life
2. Indian Pharmaceuticals
World’s 3rd largest [volume]
6th largest market globally [size]
2.4% of the Global Pharma Industry
Domestic demand [2014-15] close to $36.8 billion
cCAGR 13%, to continue for the next 5 years
90% of drugs sold estimated to be generics
1
3. KEY STRENGTHS
Fair protection of intellectual property rights
Strong manufacturing base.
Drug prices 1/10th of international price and 40 % cheaper to set up plants.
60-70% cheaper for bulk drug production.
Highly trained pool of scientists and professionals.
Highest quality approvals from USFDA
Growing biotechnology industry.
Low labour cost
2
14. Growth drivers
Demand Side
Drivers
Policy Support
Supply Side
Drivers
Cost advantage
Manufacturing hub
546 sites registered
Penetration of chemists
Accessibility to improve
Health insurance
Stress related disease
Diagnostic facilities
Reduction in approval
time
Pharma education
Accessibility for BPL
Exemptions
10
15. Key challenges
Drug Quality, not adhering to cGMP
Clinical trial quality
Low margin of profits due to Govt pricing policy – Drug price control order
Patent issues
Low input for R & D
USFDA checks
11
16. Opportunities
$44 billion lose due to patent expiry in US
Expansion of Biosimilars and Bio-pharmaceuticals.
Growth of CRAMS
NMITLI & DPRP schemes
Fiscal incentives to R &D units
12
17. India’s share in anda approvals
370
398
433
418 421
442
499
380 379
59
21%
28%
29% 30% 31%
35%
40%
43%
34%
41%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
0
100
200
300
400
500
600
2006 2007 2008 2009 2010 2011 2012 2013 2014 YTD 2015
Total Approvals India as a % of total approvals
13
18. BIOSIMILAR : THE next big thing
Active
Ingredients
sourced
from living
organisms
Sensitive to
storage and
handling
Approval –
Multi step
process
Complex
nature –
Not easily
copied
USD 1.4
billion by
2016
Overall
market
sales – 20%
growth
Cadila
Biocon
Dr Reddy’s
Lupin
WockhardtCadila’s
Exemptia,
biosilmilar
of Humira
14
3rd largest pharmaceuticals market by 2020.
20% of global exports in generics.
USD 45 Billion in revenue by 2020.
USD 26.1 Billion in generics by 2016.
USD 200 Billion to be spent on infrastructure by 2024.
49% of all drug master filings registered in the USA
The Drugs and Cosmetics Act, 1940 (Drugs Act) and Drugs and Cosmetic Rules, 1945 (Drug rules) regulate the
import, manufacture, distribution and sale of drugs in India. Under the provisions of these Acts, the Centre appoints
the Drugs Technical Advisory Board (DTAB) to advise the central government and the state governments on
technical matters.
The responsibility to enforce the Drugs Act is entrusted with both the central government and the respective state
governments. Under the Drugs and Cosmetics Act, state authorities are responsible for regulating the manufacturing,
sale and distribution of drugs, whereas the central authorities are responsible for approving new drugs and clinical
trials, laying down the standards for drugs, controlling the quality of imported drugs and coordinating
the activities of
state drug control organisations.
The Drugs Controller General of India (DCGI) is the central body that coordinates
the activities of state drug control
organisations, formulates policies and ensures uniform implementation of the Drugs Act throughout India. It is also
responsible for approval of licenses of specified categories of drugs, such as blood and blood products, IV Fluids,
Vaccine and Sera.
Indian pharmaceuticals industry is mainly regulated on the basis of patents, price and quality
Source: CRISIL
Patents
Before 2005, the regulatory system in India focused only on process patents. Indian pharmaceutical companies
thrived during the process patent regime. They would reengineer
products of global innovator companies, which were
unavailable in India, and launch them in the country as generics, as India did not recognise the product patents. In
this manner, Indian companies gained process chemistry skills, but did not focus on R&D for new drug discovery.
In January 2005, India complied with the World Trade Organisation (WTO) to follow the product patent regime [sale of
reengineered
products (for drugs patented after 1995) is restricted]. However, enterprises, which had made
significant investments and were producing and marketing the concerned product prior to January 1, 2005 and which
continue to manufacture the product covered by the patent on the date of grant of the patent, are protected, and the
patentee cannot institute infringement suits against them, but would be entitled to reasonable royalty.
For a detailed analysis on the product patent regime and its impact, please refer to the Thematic Coverage section.
Drug prices
The Drug Price Control Order (DPCO) fixes the ceiling price of some APIs and formulations. APIs and formulations
falling under the purview of the legislation are called scheduled drugs and scheduled formulations. The National
Pharmaceutical Pricing Authority (NPPA) collects data and studies the pricing structure of APIs and formulations and accordingly makes recommendations to the Ministry of Chemicals and Fertilisers.
The new Pharmaceutical Policy, notified in 2012, intends to bring 348 essential drugs in the National List of Essential
Medicines (NLEM), under the purview of the DPCO. With this policy, the market size of drugs under price control will
increase from 1520
per cent of the domestic formulations market to 2030
per cent. The policy also introduces a
radical change in the mechanism of control: shifting from the current costbased
control to a marketbased
price
mechanism.
Under the policy, the ceiling price for each drug under control would be fixed as the simple average price of brands
having more than 1 per cent market share (by value) in the sales (MAT Moving
Annual Turnover) of that particular
molecule. Thus, prices of brands which are higher than this ceiling will need to be lowered. The ceiling prices will be
allowed an annual increase as per the Wholesale Price Index (WPI). Prices will be recalculated using MAT only once
in five years or when the NLEM is updated.
Price of drugs that were part of the earlier policy, but do not come under the current policy, would be frozen for a year
and, thereafter, allowed a maximum annual increase of 10 per cent. A 10 per cent increase would also be the limit for
prices of drugs outside the government's price control.
Quality
No drug can be imported, manufactured, stocked, sold or distributed in India unless it meets the quality standards
laid down in the Drugs Act. All companies have to comply with Schedule M of the Act, which outlines various
requirements for manufacturing drugs and pharmaceuticals by applying cGMP (current Good Manufacturing Practice).
cGMP has to be followed for control and management of manufacturing and quality control testing of drugs.